2023
Notification of cessation of securities – PYC
Results of Annual General Meeting
2023 AGM Chairman’s Address and CEO Presentation
Annual General Meeting – Conference Call
Kidney Disease Program Presentation
Supplementary Information
New Drug For Major Kidney Disease Effective In Human Models
PYC and FDA Align On Clinical Trial Pathway in ADOA
RP11 Clinical Trial Dosing Completed In Patient Cohort 2
Quarterly Activities/Appendix 4C Cash Flow Report
Notice of Annual General Meeting/Proxy Form
PYC Presenting on PYC-001 Program at OTS 2023 Meeting
Notification regarding unquoted securities – PYC
Investor Presentation ADOA Program
PYC-001 Effective In Both NHPs and Patient-Derived Models
Q3 Investor Call Presentation
Corporate Presentation 2023
2022
Successful toxicology studies pave way for human trials
SEPTEMBER 2022 QUARTERLY REPORT AND APPENDIX 4C CASH FLOW REPORT
PYC Presenting On Drug Delivery Platform at Oligonucleotide Therapeutic Society 2022 Meeting
NEW CENTRAL NERVOUS SYSTEM (CNS) DRUG PROGRAM ADDED TO PYC’S PIPELINE
PYC Q3 2022 Shareholder Update
PYC Q3 2022 Investor Call 18 Aug 2022
June 2022 Quarterly Report and Appendix 4C Cash Flow Report
PYC Q2 2022 Corporate Presentation
PYC Q1 2022 Corporate Presentation
PYC Q2 2022 Investor Call 31 May 2022
Exemplary PK Study Results move RP11 Program closer to First In Human Trials
March 2022 Quarterly Report and Appendix 4C Cash Flow Report (Q1 2022)
PYC COMPLETES PRE-IND ENGAGEMENT WITH THE FDA IN THE RP11 PROGRAM
PYC Q1 2022 Investor Call 17 March 2022
December 2021 Quarterly Report and Appendix 4C Cash Flow Report
2021
Recording of CEO’s Presentation at 2021 AGM
Annual General Meeting – Conference Link
NHP Safety and Tolerability
September 2021 Quarterly Report and Cash Flow
Retina Target Engagement Confirmed in Large Eye
Upcoming Poster Presentations at TIDES USA and OTS 2021
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Ophthalmology-Focused Clinical Advisory Board
PYC Quarterly Investor Call – August 17
August Investor Conferences
Quarterly Activities/Appendix 4C Cash Flow Report
Commencement of Larger Animal Studies for Lead Program
Comprehensive Preclinical Results for VP-002 Program
VP-002 Program – Technical Presentation
New U.S. Headquarters, and Residency at Johnson & Johnson Innovation, JLABS
Second Drug Program Progressing Towards Human Trials
Evercore ISI GenomeRx Emerging Therapeutic Company Day
Second Drug Program – Efficacy Data in Patient Cell Models
PYC Invited to Present at ARVO 2021 Annual Meeting
Set To Announce Efficacy Results For Second Drug Program
March 2021 Quarterly Report and Cashflow
April Investor Call Presentation
Preclinical Data – Superior PPMO Delivery to the Brain
Quarterly Investor Call – 15th April 2021
PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board
Participation in SVB Leerink Biopharma Private Co Connect
PYC Appoints US Biotech Veteran to its Board of Directors
Lead Investigational Drug Demonstrates Key Improvement
PYC Expands US Executive Leadership Team
Progress US Clinical Stage Company and Corporate Objectives
PYC to Participate in RNA Discussion – BIO CEO Conference
December 2020 Quarterly Report and Cashflow
ICR Conference Presentation
PYC to Present at ICR Westwicke Conference
2020
Visual Evidence of Lead Drugs Efficacy
Letter to Shareholders from the US CEO
Appointment of Chief Executive Officer in the United States
PYC to Present at the Evercore ISI Conference
Grants Awarded to Support Clinical Progression of Lead Drug
FDA Response to Orphan Drug Designation Request
Successful Institutional Entitlement Offer and Placement
PYC Equity Raising to Raise Up to $55 Million
New Drug for Substantial Unmet Need Added to Pipeline
Investor Call 15th Oct 2020 12pm AEDT 9am AWST
PYC’s Lead Drug Effective in Patient Derived Models Tested
Second Potential Blockbuster Drug Added to PYC’s Pipeline
Creation of Novel Gene Therapy Delivery Technology
Executive Re-structure Across Global Operations
Appointment of world-renowned Chief Scientific Officer
Investor Call – 8am AWST – Wednesday 12 August 2020
June 2020 Quarterly Activity Report and Cashflow
Successful Dose Response & Toxicity Studies in Lead Program
PYC Recruits High Profile Chief Medical Officer to US Ops
World Class Results – Lions Eye Institute News Release
March 2020 Quarterly Activities and Cash Flow Report
Efficacy and Toxicity Studies Presentation
Successful Toxicity Results Confirm Safety Advantage
Investor Call 9.00am AWST Wed 1 April 2020
NHMRC Grand for Identifying new Antisense Drugs
CEO Appointment & Establishment of US Office
Investor Call 27 February 2020
Expansion of Drug Development Pipeline
Quarterly Shareholder Update
2019
Drug Delivery Greater than 100% more Effective – Amended
Change in Substantial Holding
Drug Delivery Greater than 100%
Conclusion of Genentech Antimicrobial Collaboration
PYC Increases Shareholding in Vision Pharma
$26.8M Fully Underwritten accelerated Entitlement Offer
Drug Delivery Greater than 100%
Presentation Oligonucleotide Therapeutics Society Meeting
Succesfful Major Milestone – Human Retina in a Dish Model
Strategic Partnership and Lead Program
Successful Time-Course Studies in Animals
Scientific Advisory Board Appointment
Successful Competitive Drug Evaluation in Animals
Successful Time – Course Studies in Animals
Phylogica’s Technology is Effective in Human Cells
Operational Update and Appendix 4c
Animal Models – 400% Outperformance of Gold Standard
Break Through Animal Model Results
March 2019 Quarterly Operational Update
Scientific Advisory Board Appointment
